

10 JUNE 2014, 17:35 AM CET

Cardio3 BioSciences Receives Authorization to Enroll Patients in Sweden in its Phase III Clinical Trial CHART-1

- **CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart failure**
- **To date, ten countries have granted authorization for Cardio3 BioSciences' Phase III (CHART-1)**

Mont-Saint-Guibert, Belgium - Cardio3 BioSciences SA (C3BS) (*Euronext Brussels and Euronext Paris : CARD*), leader in the discovery and development of advanced regenerative therapies for heart disease, today announces it has received authorization from the Swedish Medical Products Agency (LÄKEMEDELSVERKET) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Sweden.

After the recent authorization in Ireland, and earlier in United Kingdom, Belgium, Israel, Serbia, Hungary, Spain, Italy, Poland and Ireland, Sweden is the tenth country to have authorized this unique study, which aims to treat ischemic congestive heart failure.

The CHART-1 trial (Congestive Heart failure Cardiopoietic Regenerative Therapy) represents the world's first Phase III trial for a pre-programmed cellular therapy for the treatment of heart failure.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said: *"We are very pleased with the progress of our Phase III clinical study. Adding another European country will enable us to pursue the CHART-1 study according to our objectives."*

The Phase III trial is a prospective, multi-centre, randomized, sham-controlled, patient-and evaluator-blinded study comparing treatment with C-Cure® to a sham treatment. The trial will recruit a minimum of 240 patients with chronic advanced symptomatic heart failure. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at 9 months post-procedure.

*** END ***

10 JUNE 2014, 17:35 AM CET

For more information contact:

Cardio3 BioSciences

Dr Christian Homsy, CEO

Anne Portzenheim, Communication Manager

www.c3bs.com

Tel : +32 10 39 41 00

aportzenheim@c3bs.com**Citigate Dewe Rogerson**

Chris Gardner

Tel : +44 (0) 207 638 9571

About Cardio3 BioSciences

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the USA and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure[®] is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure[®] consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to regenerate the heart. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath_{ez}[®], the most technologically injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities. As a result, of these factors investors and prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or review any forward-looking statement, whether as a result of new information, future events or otherwise.
